The AIDS epidemic, initially recognized in the early 1980's, currently affects more than 35 million people worldwide. Infection with the human immunodeficiency virus (HIV) is associated with a wide range of long term health complications including the development of cancer, currently a major cause of death among persons living with HIV/AIDS. The early form of the AIDS and Cancer Specimen Resource (ACSR) was established in 1994 as a cooperative agreement with the NCI with a mission to provide high quality biospecimens to researchers, a mission still paramount for the current ACSR. Principle investigators (MPIs) from the two legacy sites (GWU and UCSF) oversee the function of the ACSR to ensure the adherence to NCI best practices in this multinational program. The ACSR is currently the custodian for specimen collections from more than 20,000 individuals and makes these biospecimens available to eligible researchers studying HIV and cancer through an established specimen application process. In the past five years, investigators from more than 50 institutions have received research material from the ACSR. In addition, the ACSR has provided the centralized biospecimen collection and distribution functions for the AIDS Malignancy Consortium (AMC), which represents the NCI-funded international network of more than 30 clinical institutions involved in testing novel cancer therapies in HIV-infected individuals. The ACSR is structured into regional biospecimen repositories (RBRs) located in distinct geographical regions that reflect the US and global HIV epidemic and are unified (virtually) by an informatics infrastructure managed by the Hub for Integrated Informatics and Research Support (HIIRS). The RBRs are distinct but complementary in their diverse functions, with collaborative interactions fostered through the Governing Committee and ACSR-wide Working Groups that accomplish activities related to Science and Technology, Marketing and Outreach, Informatics, and Quality Management. As the HIV epidemic has evolved the types of cancers and the technologies used to study them have also changed. The newly reconfigured ACSR will have two divisions, both focused on obtaining the most important well-annotated (demographic, clinical, pathological and outcomes data) biospecimens for research as defined by investigator inquiries and the ACSR's scientific advisory board. The two MPIs, respectively will head the national and international AMC support program and the scientific direction of the ACSR. Both MPIs will work within the structure of the ACSR to obtain and provide to researcher's specimens most important for research in the current epidemic.
Specific Aims i nclude: 1) Acquire, store, and equitably distribute tumor tissues and biological fluids from individuals with HIV-associated malignancies (AIDS-defining cancers and non-AIDS defining cancers) to meet the biospecimen needs of researchers in HIV-associated malignancies; and 2) Promote the success of AMC clinical trials through mutually beneficial collaborations.

Public Health Relevance

The AIDS Cancer and Specimen Resource (ACSR) will supply biospecimens and clinical data to individuals investigating HIV associated cancers. It will also support the AIDS Malignancy Clinical Trials Consortium (AMC) by providing support for its biorepository functions in the United States, sub-Saharan Africa, and Latin America.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Liddell Huppi, Rebecca
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
George Washington University
Schools of Medicine
United States
Zip Code
Lamers, Susanna L; Fogel, Gary B; Liu, Enoch S et al. (2018) Brain-specific HIV Nef identified in multiple patients with neurological disease. J Neurovirol 24:1-15
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Mwimanzi, Francis; Toyoda, Mako; Mahiti, Macdonald et al. (2018) Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol 92:
Ayers, Leona W; Barbachano-Guerrero, Arturo; McAllister, Shane C et al. (2018) Mast Cell Activation and KSHV Infection in Kaposi Sarcoma. Clin Cancer Res 24:5085-5097
Vasquez, Joshua J; Hussien, Rajaa; Aguilar-Rodriguez, Brandon et al. (2018) Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. J Histochem Cytochem 66:427-446
Castillo-Mancilla, Jose R; Morrow, Mary; Boum, Yap et al. (2018) Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. J Acquir Immune Defic Syndr 77:507-513
Lee, Guinevere Q; Bangsberg, David R; Mo, Theresa et al. (2017) Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. AIDS 31:2345-2354
Schneider, Johann W; Dittmer, Dirk P (2017) Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol 18:529-539
Yanik, Elizabeth L; Kaunitz, Genevieve J; Cottrell, Tricia R et al. (2017) Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. JAMA Oncol 3:974-978
McCluskey, Suzanne M; Boum 2nd, Yap; Musinguzi, Nicholas et al. (2017) Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. J Acquir Immune Defic Syndr 76:183-187

Showing the most recent 10 out of 39 publications